The potential for senotherapies to abate atherosclerosis is also provided by the studies of Roos et al., using ApoE−/− mice, an alternative model of atherogenesis; treatment with dasatinib and querectin reduces senescence cell burden and plaque calcification but does not influence plaque size [158]. This evidence concerns the gene APOE and atherosclerosis.